When they feel better (or worse), they have no idea which supplement contributed
As demand surges for semaglutide alternatives like compounded GLP-1 medications, telehealth platforms, compounding pharmacies, and personalized medicine are exposing cracks in the FDAs regulatory systemand reshaping the future of pharma
According to the Food and Drug Administration (FDA), around 70% of American adults are overweight or clinically obese
Emerging reviews have identified concerns about inadequate protein and micronutrient intake in some GLP-1 users, particularly when nausea, food aversion, or prolonged restriction is present
Xia X, Lin Q, Zhou Z, Chen Y